Genetic Signatures

5 EasyScreen ™ detection kits available for sale in Europe and UK. An application to the Therapeutic Goods Administration (TGA) for STI kit registration was also lodged and is currently pending approval. Additionally, clinical trials in the USA for the Enteric Protozoan test kit have continued to advance to support an application to the US FDA to be able to sell this product in the largest molecular diagnostics market in the world. Overall, Genetic Signatures had made great strides since its ASX listing in March 2015. Sales have increased from $1.8m in the first year of listing to $28.3m this financial year, and as reported in July, a very strong start to FY2022 sets up your company for the year ahead. Perhaps not surprisingly, recent interest in - and understanding of - molecular diagnostics has increased markedly as a result of the SARS-CoV-2 testing opportunities. I would like to recognise the outstanding commitment and stewardship of our Board. On the personnel front, we were delighted at the appointment of Dr Neil Gunn as a new director. Dr Gunn brings 30 years of medical device and diagnostics experience to the Company and most recently was President of Roche Sequencing Solutions (a business unit of Roche Diagnostics). A search is underway for additional Directors, to further strengthen our Board. On behalf of the Genetic Signatures board, I wish to sincerely thank the management team and all employees for their excellent work amid difficult conditions. In particular the board acknowledges Dr John Melki’s outstanding ongoing leadership. I would also like to thank shareholders for their ongoing support and look forward to updating the market on the next exciting chapters of the unfolding Genetic Signatures story. Dr Nick Samaras Chairman